<DOC>
	<DOCNO>NCT00833846</DOCNO>
	<brief_summary>Type II diabetes mellitus rapidly become global pandemic deleterious impact cardiovascular morbidity mortality . Understanding pathophysiology important development future therapeutic intervention . Emerging evidence suggest interplay mitochondrial dysfunction development insulin resistance . Interestingly , mitochondrial dysfunction skeletal muscle adipose tissue early event development type II diabetes mellitus propose play role exacerbate insulin resistance . Although demonstrated skeletal muscle insulin-resistant individual reduce mitochondrion mitochondrial dysfunction , whether disruption mitochondrial function widespread explore . We hypothesize disruption mitochondrial function systemic thereby may contribute development peripheral insulin resistance possibly promote myriad complication associate diabetes . To test assumption , propose initial proof concept study evaluate mitochondrial biology human platelet normal volunteer , pre-diabetic diabetic subject ass whether mitochondrial disruption/dysfunction evolve progression type II diabetes . In parallel , proteomic analysis perform evaluate whether development insulin resistance diabetes confers specific modulation biological signature human platelet disease progression . To delineate concept , evaluate study subject 's glucose tolerance insulin sensitivity draw blood parallel study platelet . Biological readouts include : 1 ) quantification mitochondrial proteome electron transfer chain content ; 2 ) evaluation platelet mitochondrial respiratory function 3 ) determine mitochondrial reactive oxygen specie capacity defenses . If hypothesis validate , study show mitochondrial disruption/dysfunction generalize find type II diabetes . Additionally , would propose use platelet potential biomarkers early detection mitochondrial function assessment disease . Finally , would establish peripheral blood readout modification mitochondrial function novel approach monitor prevention and/or reversal insulin resistance diabetes response therapeutic strategy .</brief_summary>
	<brief_title>Pilot Study Mitochondrial Biology Human Platelets</brief_title>
	<detailed_description>Type II diabetes mellitus rapidly become global pandemic deleterious impact cardiovascular morbidity mortality . Understanding pathophysiology important development future therapeutic intervention . Emerging evidence suggest interplay mitochondrial dysfunction development insulin resistance . Interestingly , mitochondrial dysfunction skeletal muscle adipose tissue early event development type II diabetes mellitus propose play role exacerbate insulin resistance . Although demonstrated skeletal muscle insulin-resistant individual reduce mitochondrion mitochondrial dysfunction , whether disruption mitochondrial function widespread explore . We hypothesize disruption mitochondrial function systemic thereby may contribute development peripheral insulin resistance possibly promote myriad complication associate diabetes . To test assumption , propose initial proof concept study evaluate mitochondrial biology human platelet normal volunteer , pre-diabetic diabetic subject ass whether mitochondrial disruption/dysfunction evolve progression type II diabetes . In parallel , proteomic analysis perform evaluate whether development insulin resistance diabetes confers specific modulation biological signature human platelet disease progression . To delineate concept , evaluate study subject 's glucose tolerance insulin sensitivity draw blood parallel study platelet . Biological readouts include : 1 ) quantification mitochondrial proteome electron transfer chain content ; 2 ) evaluation platelet mitochondrial respiratory function 3 ) determine mitochondrial reactive oxygen specie capacity defenses . If hypothesis validate , study show mitochondrial disruption/dysfunction generalize find type II diabetes . Additionally , would propose use platelet potential biomarkers early detection mitochondrial function assessment disease . Finally , would establish peripheral blood readout modification mitochondrial function novel approach monitor prevention and/or reversal insulin resistance diabetes response therapeutic strategy .</detailed_description>
	<mesh_term>Insulin Resistance</mesh_term>
	<criteria>ELIGIBILITY CRITERIA : Inclusion Criteria ( young control group ) : 1 . Adults old 21 year less 40 year . 2 . Insulin sensitivity fast glucose less 100 mg/dl 2hour post oral glucose tolerance test blood glucose le 140 mg/dl . 3 . Subject understands protocol provide write , informed consent . Inclusion Criteria ( young insulinresistant group ) : 1 . Adults old 21 year less 40 year . 2 . Insulin resistance define fast blood sugar great equal 100mg/dl less 125 mg/dl and/or 2hour post oral glucose tolerance test blood glucose great 140 mg/dl less 200 mg/dl . 3 . Subject understands protocol provide write , informed consent . Inclusion Criteria ( middle age control group ) : 1 . Adults great equal 40 year less equal 60 year . 2 . Insulin sensitivity fast blood glucose le 100 mg/dl 2hour post oral glucose tolerance test blood glucose le 140 mg/dl . 3 . Subject understands protocol provide write , informed consent . Inclusion Criteria ( middle age insulinresistant group ) : 1 . Adults great equal 40 year less equal 60 year . 2 . Insulin resistance define fast blood sugar great equal 100mg/dl less 125 mg/dl and/or 2hour post oral glucose tolerance test blood glucose great 140 mg/dl less 200 mg/dl . 3 . Subject understands protocol provide write , informed consent . Inclusion Criteria ( middle age type II diabetes group ) : 1 . Adults great equal 40 year less equal 60 year . 2 . Type II diabetes define fast blood sugar great 125 mg/dl and/or 2hour post oral glucose tolerance test blood glucose great 200 mg/dl untreated and/or subject oral hypoglycemic agent therapy HbA1c great 6.7 percent . 3 . Subject understands protocol provide write , informed consent . Exclusion Criteria ( study subject ) : 1 . Uncontrolled hypertension , heart failure , unstable coronary artery disease symptomatic peripheral arterial disease require change medication medical intervention precede 3 month . 2 . Insulindependant diabetes mellitus current use thiazolidinediones . 3 . Women childbearing age unless recent pregnancy test negative breast feeding . 4 . Serum creatinine great 2.5 mg/dl . 5 . Liver transaminase level great 2.5 time upper limit normal . 6 . History cancer treat chemotherapy irradiation last 5 year . 7 . Active inflammatory disease , infection , abnormal white blood cell differential . 8 . Enrollment drug study within last 30 day . 9 . BMI great 35 middle age group great 30 young subject . 10 . Age great 60 year . 11 . Another member potential study subject 's immediate family recruited/participated study . 12 . The use anticoagulation therapy , thiazide diuretic , corticosteroid , psychiatric drug stop medical reason day study participation .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 24, 2011</verification_date>
	<keyword>Mitochondria Platelets</keyword>
	<keyword>Mitochondria Diabetes</keyword>
	<keyword>Insulin Resistance Mitochondria</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Insulin Resistance</keyword>
</DOC>